Joseph T Kannarkatt - WellSpan Health

Dr. Joseph Kannarkatt

Claim this profile

WellSpan Medical Oncology and Hematology

Studies Lung Cancer
Studies Lung Carcinoma
7 reported clinical trials
31 drugs studied

Area of expertise

1Lung Cancer
Joseph Kannarkatt has run 5 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Carcinoma
Joseph Kannarkatt has run 2 trials for Lung Carcinoma. Some of their research focus areas include:
Stage IV
EGFR negative
ALK negative

Affiliated Hospitals

Image of trial facility.
WellSpan Medical Oncology And Hematology
Image of trial facility.
Adams Cancer Center

Clinical Trials Joseph Kannarkatt is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Joseph Kannarkatt

Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Joseph Kannarkatt has experience with
  • Osimertinib
  • Nab-paclitaxel
  • Biospecimen Collection
  • Bevacizumab
  • Paclitaxel
  • Pertuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Joseph Kannarkatt specialize in?
Is Joseph Kannarkatt currently recruiting for clinical trials?
Are there any treatments that Joseph Kannarkatt has studied deeply?
What is the best way to schedule an appointment with Joseph Kannarkatt?
What is the office address of Joseph Kannarkatt?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security